Literature DB >> 24125567

The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.

Markus Axelsson1, Niklas Mattsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke.   

Abstract

We investigated the impact of disease duration, clinical course and immunosuppressive therapy on intrathecal IgG synthesis in multiple sclerosis (MS). Cerebrospinal fluid (CSF) was obtained twice, 8-10 years apart, from 20 MS patients and 26 healthy controls, and from 22 MS patients before and after two years of mitoxantrone treatment. The oligoclonal IgG band patterns changed in 15 patients at long-term follow-up, but were only influenced in 4 patients by mitoxantrone therapy. The CSF B-cell-regulating chemokine CXCL13 correlated with intrathecal IgG production suggesting a B-cell-dependence of intrathecal IgG synthesis in MS.
© 2013.

Entities:  

Keywords:  B-cell; CXCL13; Intrathecal IgG; Mitoxantrone; Multiple sclerosis; Oligoclonal band (OCB)

Mesh:

Substances:

Year:  2013        PMID: 24125567     DOI: 10.1016/j.jneuroim.2013.09.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band.

Authors:  Diana Ferraro; Diego Franciotta; Roberta Bedin; Claudio Solaro; Eleonora Cocco; Mario Santangelo; Paolo Immovilli; Alberto Gajofatto; Massimiliano Calabrese; Massimiliano Di Filippo; Riccardo Orlandi; Anna Maria Simone; Francesca Vitetta; Elisabetta Capello; Debora Giunti; Alessandra Murialdo; Jessica Frau; Sara Mariotto; Antongiulio Gallina; Claudio Gasperini; Patrizia Sola
Journal:  J Neurol       Date:  2017-04-05       Impact factor: 4.849

Review 2.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

3.  Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.

Authors:  Mika Komori; Andrew Blake; Mark Greenwood; Yen Chih Lin; Peter Kosa; Danish Ghazali; Paige Winokur; Muktha Natrajan; Simone C Wuest; Elena Romm; Anil A Panackal; Peter R Williamson; Tianxia Wu; Bibiana Bielekova
Journal:  Ann Neurol       Date:  2015-04-16       Impact factor: 10.422

Review 4.  B-cell Therapy for Multiple Sclerosis: Entering an era.

Authors:  Ariele L Greenfield; Stephen L Hauser
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422

5.  Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis.

Authors:  Simona Perga; Alessandra Giuliano Albo; Katarzyna Lis; Nicoletta Minari; Sara Falvo; Fabiana Marnetto; Marzia Caldano; Raffaella Reviglione; Paola Berchialla; Marco A Capobianco; Maria Malentacchi; Davide Corpillo; Antonio Bertolotto
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 6.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08

Review 7.  Vitamin D and Neurological Diseases: An Endocrine View.

Authors:  Carolina Di Somma; Elisabetta Scarano; Luigi Barrea; Volha V Zhukouskaya; Silvia Savastano; Chiara Mele; Massimo Scacchi; Gianluca Aimaretti; Annamaria Colao; Paolo Marzullo
Journal:  Int J Mol Sci       Date:  2017-11-21       Impact factor: 5.923

Review 8.  Biomarkers of therapeutic response in multiple sclerosis: current status.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

9.  Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.

Authors:  Evanthia Bernitsas; Omar Khan; Sara Razmjou; Alexandros Tselis; Fen Bao; Christina Caon; Scott Millis; Navid Seraji-Bozorgzad
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

10.  Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts.

Authors:  Miriam Schlüter; Eva Oswald; Stephan Winklmeier; Ingrid Meinl; Joachim Havla; Peter Eichhorn; Edgar Meinl; Tania Kümpfel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.